Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PainChek Ltd ( (AU:PCK) ) just unveiled an announcement.
PainChek Ltd has issued 176,471 fully paid ordinary shares to directors under a previously announced placement to sophisticated, professional and other exempt investors, following shareholder approval at its 2025 Annual General Meeting. The company has confirmed that the shares were issued without a prospectus under the Corporations Act exemption, that it is up to date with its financial reporting and continuous disclosure obligations, and that there is no undisclosed price-sensitive information, providing assurance to the market and existing shareholders about regulatory compliance and transparency around the capital raising.
More about PainChek Ltd
PainChek Ltd is a medical technology company that has developed PainChek, the world’s first regulatory-cleared medical device app for assessing pain in people who cannot reliably self-report, those who can, and those whose ability fluctuates. Delivered via smartphones and tablets, the AI-driven tool automates multidimensional pain assessment, integrates the Numerical Rating Scale and feeds into the PainChek Analytics reporting suite. The platform has regulatory clearance across multiple major markets including Australia, the EU, the UK and the US, is used in more than 1,900 aged care facilities worldwide, and supports clinicians, carers and nurses in managing pain in adults with dementia, disability and other conditions, as well as infants and people receiving home and disability care.
Average Trading Volume: 461,214
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$58.47M
For detailed information about PCK stock, go to TipRanks’ Stock Analysis page.